Royal London Asset Management Ltd. Raises Holdings in Boston Scientific Corporation $BSX

Royal London Asset Management Ltd. boosted its position in Boston Scientific Corporation (NYSE:BSX) by 13.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 753,076 shares of the medical equipment provider’s stock after purchasing an additional 87,185 shares during the quarter. Royal London Asset Management Ltd. owned about 0.05% of Boston Scientific worth $32,141,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific in the second quarter valued at about $25,000. FWL Investment Management LLC acquired a new position in Boston Scientific during the second quarter worth about $26,000. Swiss RE Ltd. purchased a new stake in Boston Scientific during the 4th quarter valued at about $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific in the 4th quarter valued at about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new stake in Boston Scientific in the 1st quarter valued at about $28,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.3%

Shares of NYSE BSX opened at $46.82 on Friday. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The stock has a market cap of $67.85 billion, a P/E ratio of 18.96, a PEG ratio of 1.02 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The business’s fifty day simple moving average is $46.56 and its 200-day simple moving average is $56.65.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a share buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney purchased 186,240 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director David C. Habiger bought 2,100 shares of the stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 194,522 shares of company stock valued at $9,385,210. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on BSX shares. Barclays lowered their target price on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. Royal Bank Of Canada reduced their price objective on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, July 30th. Argus reissued a “hold” rating on shares of Boston Scientific in a research note on Friday, July 31st. TD Cowen reiterated a “buy” rating and set a $56.00 price target on shares of Boston Scientific in a report on Tuesday. Finally, UBS Group lowered their price target on shares of Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.